NIH's Rx: Stem Cells for Trojan Horse Vaccine Disease (real)

[Mort Zuckerman]

To: kathleen...@hhs.gov, francis...@nih.hhs.gov,
margaret...@fda.hhs.gov, dwh...@forbes.com,
ca...@drcarolgoodheart.com, lPick...@cdc.gov, Durlan...@yale.edu,
Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, margaret...@hhs.fds.gov,
emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@ct.gov, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@ct.gov, kur...@washpost.com, georg...@washpost.com,
p...@allegorypress.com, commissi...@po.state.ct.us,
brans...@comcast.net, vts...@comcast.net, o...@po.state.ct.us,
freet...@charter.net, scott....@po.state.ct.us,
govern...@po.state.ct.us, attorney...@ct.gov,
randall...@usdoj.gov, Robert....@yale.edu, editor@greenwich-
post.com, harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, saint....@sbcglobal.net
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, bmi...@newstimes.com, tr...@hotmail.com,
rast...@aol.com, billc...@gmail.com, amcg...@rms-law.com,
rjmu...@aol.com, paulcrai...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com

Subject: NIH's Rx: Stem Cells for Trojan Horse Vaccine Disease (real)

Date: Sep 16, 2011 6:11 AM

ARTICLE BELOW
===========================

LYMErix vaccination causes the
activation of Epstein-Barr via
immunosuppression.

The "Controversy" is the Trojan
Horse (Great Imitator) Vaccine -
LYMErix.


The Yale Lyme crooks are in chronic
hysteria because not only are they
an example of the stupidity associated
and Yale's Mysogynopsychopathy (its
dominant culture), but they've been
defunded. There is no real platform
for them to reissue their redundant
and perpetual "Lyme Isn't ________
[fill in the blank]" reports.

======================

http://www.ncbi.nlm.nih.gov/pubmed/21454450

Blood. 2011 Jun 2;117(22):5835-49. Epub 2011 Mar 31.
Characterization and treatment of chronic active Epstein-Barr virus
disease: a 28-year experience in the United States.
Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM,
Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP,
Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D,
Sportes C, Bishop MR, Wilson W, Straus SE.
Source

Laboratory of Infectious Diseases, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, 50 South Drive,
Bethesda, MD 20892, USA. jco...@niaid.nih.gov
Abstract

Chronic active EBV disease (CAEBV) is a lymphoproliferative disorder
characterized by markedly elevated levels of antibody to EBV or EBV
DNA in the blood and EBV RNA or protein in lymphocytes in tissues. We
present our experience with CAEBV during the last 28 years, including
the first 8 cases treated with hematopoietic stem cell transplantation
in the United States. Most cases of CAEBV have been reported from
Japan. Unlike CAEBV in Japan, where EBV is nearly always found in T or
natural killer (NK) cells in tissues, EBV was usually detected in B
cells in tissues from our patients. Most patients presented with
lymphadenopathy and splenomegaly; fever, hepatitis, and pancytopenia
were common. Most patients died of infection or progressive
lymphoproliferation. Unlike cases reported from Japan, our patients
often showed a progressive loss of B cells and hypogammaglobulinemia.
Although patients with CAEBV from Japan have normal or increased
numbers of NK cells, many of our patients had reduced NK-cell numbers.
Although immunosuppressive agents, rituximab, autologous cytotoxic T
cells, or cytotoxic chemotherapy often resulted in short-term
remissions, they were not curative. Hematopoietic stem cell
transplantation was often curative for CAEBV, even in patients with
active lymphoproliferative disease that was unresponsive to
chemotherapy. These studies are registered at http://www.clinicaltrials.gov
as NCT00032513 for CAEBV, NCT00062868 and NCT00058812 for EBV-specific
T-cell studies, and NCT00578539 for the hematopoietic stem cell
transplantation protocol.

PMID:
21454450
[PubMed - indexed for MEDLINE]
PMCID: PMC3112034
[Available on 2012/6/2]

Publication Types, MeSH Terms, Substances, Secondary


KMDickson